Table 8.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 748 919 861 853 972 943 914 891 905 870
Tx with Antirejection Treatments 495 622 566 317 287 262 232 194 192 154
Antibodies Any in Category 65.9% 47.6% 31.3% 46.7% 44.3% 42.0% 41.4% 32.0% 50.5% 57.8%
ALG 17.4% 8.4% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 2.0% 6.9% 8.8% 18.3% 10.1% 6.5% 3.9% 0.5% 2.6% 1.9%
OKT3 60.4% 41.5% 24.7% 34.7% 35.5% 24.4% 22.8% 12.4% 10.4% 9.7%
Thymoglobulin 0.0% 0.0% 0.0% 0.3% 3.1% 16.0% 15.1% 20.6% 33.9% 39.6%
Zenapax 0.0% 0.0% 0.0% 0.3% 1.7% 1.5% 1.7% 1.0% 4.7% 11.7%
Simulect 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 2.2% 0.5% 1.0% 1.3%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 3.9%
Corticosteroids Any in Category 76.4% 66.2% 55.1% 69.1% 77.4% 80.5% 82.8% 86.6% 76.6% 68.8%
Steroids 76.4% 66.2% 55.1% 69.1% 77.4% 80.5% 82.8% 86.6% 76.6% 68.8%
Antimetabolites Any in Category 0.0% 0.2% 0.2% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0%
Cytoxan 0.0% 0.2% 0.2% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.